Patent intelligence · US
US 10689443
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
Patent details — US 10689443
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 23, 2020
- Expiration
- Jun 18, 2040
- Applicant
- PRECISION BIOLOGICS, INC.
- Claims
- 18
- CPC classes
- A61K, A61K2039/505, A61K39/3955, A61K45/06
Quick answer
US 10689443 (Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer) is held by PRECISION BIOLOGICS, INC.. Status: granted. Granted Jun 23, 2020. Expires Jun 18, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PRECISION BIOLOGICS, INC.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K2039/505, A61K39/3955, A61K45/06, A61P, A61P35/00
More from PRECISION BIOLOGICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12419920
Bifidobacterium longum NCIMB 41676
granted -
US 12410418
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
granted -
US 12351839
Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
granted -
US 12344676
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
granted -
US 12336835
Neuromodulation to target glucose transporter and/or incretin pathways
granted -
US 12232492
Disinfection of bacteriophages products using supercritical carbon dioxide
granted -
US 12233135
Therapeutic constructs for treating cancer
granted -
US 12180463
Lactobacillus reuteri
granted
Frequently asked questions
What is US patent 10689443?
US 10689443 (Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer) is held by PRECISION BIOLOGICS, INC.. Status: granted. Granted Jun 23, 2020. Expires Jun 18, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10689443?
PRECISION BIOLOGICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 158 pharmaceutical patents for this assignee.
When does US 10689443 expire?
Our index shows an expiration date of Jun 18, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.